Targeted therapy in her2-positive metastatic breast cancer: a review of the literature

Current Oncology

S. Verma¹  X. Zhu¹ 

[1] Sunnybrook Odette Cancer Centre, University of Toronto

关键词: her2;    metastatic breast cancer;    targeted therapy;    phase iii trials;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Breast tumours positive for her2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-her2 therapies has dramatically improved disease control and survival in patients with metastatic her2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond.The present review summarizes the currently available data on targeted anti-her2 therapies from completed randomized phase iii clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic her2-positive breast cancer.

【 授权许可】

Unknown